Prescribing Antidepressants for Elite Athletes: Is There Evidence to Support Best Practices in Sports Psychiatry? A Scoping Review
Authors:
- Rafael ZiniRZRafael Zini
- João Maurício Castaldelli-MaiaJCJoão Maurício Castaldelli-Maia
- Malte Christian ClaussenMCMalte Christian Claussen
- Maria Olivia Pozzolo PedroMaria Olivia Pozzolo Pedro
- Renner Santos BorgesRBRenner Santos Borges
- André Furtado de Ayalla RodriguesARAndré Furtado de Ayalla Rodrigues
- Lara Ferreira CamachoLCLara Ferreira Camacho
- Gustavo Bonini CastellanaGCGustavo Bonini Castellana
Open Access
- 30 June 2026
- journal article
- review article
- Published by Springer Nature in Sports Medicine - Open
- Vol. 12 (1)
Abstract
Elite athletes face unique mental health challenges, yet the use of antidepressants in this population remains underresearched. Despite the prevalence of depressive and anxiety symptoms, there are no specific pharmacological guidelines tailored to athletes’ mental health needs or performance demands. This scoping review aimed to explore the current literature on the use of antidepressant medications among elite athletes with symptoms of or who were diagnosed with depressive or anxiety disorders, focusing on treatment effectiveness, safety, performance, and, mainly, the athlete’s well-being. A systematic search of PubMed, Embase, and PsycINFO (February 18–20, 2025) was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) guidelines. Predefined terms related to athletes, antidepressants, and psychiatric disorders were employed. Studies were included if they involved elite athletes treated with antidepressants for major depressive disorder, bipolar depression, or generalized anxiety disorder. The data were charted and narratively synthesized. Among the 34,131 records screened, 15 met the inclusion criteria: 11 narrative reviews, 2 systematic reviews, 1 survey, and 1 position statement. Most studies provide recommendations on the basis of the general population, offering limited data on elite athletes with formal diagnoses. Few studies have reported treatment durations or mental health outcomes. While performance effects have been emphasized, psychological recovery is rarely addressed. Selective serotonin reuptake inhibitors—particularly escitalopram, fluoxetine, and sertraline—were the most commonly suggested drugs. There is a lack of robust evidence to guide antidepressant use among elite athletes. Future research should prioritize trials involving clinically diagnosed athletes, structured protocols, and outcomes centered on mental health and well-being rather than merely performance.Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- Acute dopamine/noradrenaline reuptake inhibition enhances human exercise performance in warm, but not temperate conditionsThe Journal of Physiology, 2005
- Paroxetine administration to influence human exercise capacity, perceived effort or hormone responses during prolonged exercise in a warm environmentExperimental Physiology, 2004
- No effect of a noradrenergic reuptake inhibitor on performance in trained cyclistsMedicine & Science in Sports & Exercise, 2002
- Selective serotonin reuptake inhibitors: Their effect on high-intensity exercise performanceArchives of Physical Medicine and Rehabilitation, 2001
- Exercise Performance is not Influenced by a 5-HT Reuptake InhibitorInternational Journal of Sports Medicine, 2001
- Isokinetic Muscle Performance in Major Depressive Disorder: Alterations by Antidepressant TherapyInternational Journal of Neuroscience, 2001
- Influence of Paroxetine, Branched-Chain Amino Acids and Tyrosine on Neuroendocrine System Responses and Fatigue in HumansHormone and Metabolic Research, 1998
- Induction of Mania with Selective Serotonin Re-uptake Inhibitors and Tricyclic AntidepressantsThe British Journal of Psychiatry, 1994
- Evidence for a possible role of 5‐hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5‐HT re‐uptake inhibitor, reduces the capacity to perform prolonged exerciseExperimental Physiology, 1992
- Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugsThe American Journal of Cardiology, 1976